Comparative Evaluation of Olopatadine Ophthalmic Solution (0.1%) Versus Ketorolac Ophthalmic Solution (0.5%) Using the Provocative Antigen Challenge Model-Reference-Cited by-同舟云学术

Comparative Evaluation of Olopatadine Ophthalmic Solution (0.1%) Versus Ketorolac Ophthalmic Solution (0.5%) Using the Provocative Antigen Challenge Model

Published:1999-12 Issue: Volume:77 Page:47-52
ISSN:1395-3907
Container-title:Acta Ophthalmologica Scandinavica
language:en
Short-container-title:

Author:

Deschenes J.,Discepola M.,Abelson M.

Publisher

Wiley

Subject

Ophthalmology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0420.1999.tb01174.x/fullpdf

Reference15 articles.

1. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy;Abelson;Surv Ophthalmol,1993

2. Number of inflammatory cells in the normal conjunctiva;Allansmith;Am J Ophthalmol,1978

3. Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?;Church;Agents Actions,1986

4. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells;Yanni;Ann Allergy Asthma Immunol,1997

5. Characterization of the ocular antiallergic and anti-histaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases;Sharif;J Pharmacol Exp Ther,1996

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on pathophysiology and managements of allergic conjunctivitis;Indian Journal of Clinical and Experimental Ophthalmology;2024-03-15

2. Ocular redness – II: Progress in development of therapeutics for the management of conjunctival hyperemia;The Ocular Surface;2021-07

3. Immune Mechanisms, Pathology, and Management of Allergic Ocular Diseases;Advanced Concepts in Human Immunology: Prospects for Disease Control;2020

4. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis;Ocular Immunology and Inflammation;2016-05-18

5. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management;Therapeutic Advances in Chronic Disease;2016-01